Markets

Audentes Therapeutics (BOLD) Jumps: Stock Rises 14.9%

Audentes Therapeutics, Inc.BOLD was a big mover last session, as the company saw its shares rise nearly 15% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company for the company-as the stock is now up 19.19% in the past one-month time frame.

The company has seen a mixed track record when it comes to estimate revisions of one increase and three decrease over the past few weeks, while the Zacks Consensus Estimate for the current quarter hasn't been in the trend either. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Audentes Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.

Audentes Therapeutics, Inc. Price

Audentes Therapeutics, Inc. Price | Audentes Therapeutics, Inc. Quote

A better-ranked stock in the Medical sector is Akari Therapeutics PLC AKTX , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .

Is BOLD going up? Or down? Predict to see what others think: Up or Down .

Zacks Editor-in-Chief Goes ""All In"" on This Stock

Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.

Download it free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Akari Therapeutics PLC (AKTX): Free Stock Analysis Report

Audentes Therapeutics, Inc. (BOLD): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AKTX BOLD

Other Topics

Investing Stocks

Latest Markets Videos